Innate Pharma
Clinical-stage biotech developing immunotherapies for cancer using the innate immune system.
IPH | PA
Overview
Corporate Details
- ISIN(s):
- FR0010331421 (+1 more)
- LEI:
- 9695002Y8420ZB8HJE29
- Country:
- France
- Address:
- 117 AVENUE DE LUMINY, 13009 MARSEILLE
- Website:
- http://www.innate-pharma.com/
- Sector:
- Manufacturing
Description
Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2012-04-26 18:11 |
Document de référence et rapport financier annuel d'Innate Pharma
|
French | 1.6 MB | ||
| 2012-04-18 07:15 |
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce aujourd’hui le la…
|
French | 32.4 KB | ||
| 2012-04-16 07:15 |
Bristol-Myers Squibb France et Innate Pharma annoncent l’organisation d’une tab…
|
French | 165.0 KB | ||
| 2012-04-16 07:15 |
Bristol-Myers Squibb France and Innate Pharma to host a roundtable event includ…
|
English | 192.7 KB | ||
| 2012-03-06 07:00 |
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce aujourd’hui ses r…
|
French | 111.2 KB | ||
| 2012-03-06 07:00 |
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) reports today its consoli…
|
English | 87.1 KB | ||
| 2012-02-07 06:50 |
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), la société de l’immunité…
|
French | 40.3 KB | ||
| 2012-02-07 06:50 |
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity comp…
|
English | 40.0 KB | ||
| 2012-01-20 06:45 |
Un nouveau mécanisme de régulation du système immunitaire impliquant les cellul…
|
French | 41.6 KB | ||
| 2012-01-20 06:45 |
Novel immune regulation mechanism involving Natural Killer Cells described and …
|
English | 40.4 KB | ||
| 2012-01-02 20:29 |
Bilan semestriel du contrat de liquidité Innate Pharma avec la société Natixis …
|
French | 33.1 KB | ||
| 2012-01-02 20:29 |
Half-year report on Innate Pharma's liquidity contract with Natixis Securities
|
English | 37.4 KB | ||
| 2011-11-04 18:27 |
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce sa participation …
|
French | 49.6 KB | ||
| 2011-11-04 18:27 |
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces its participati…
|
English | 34.3 KB | ||
| 2011-11-04 07:00 |
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce son chiffre d’aff…
|
French | 36.1 KB |
Automate Your Workflow. Get a real-time feed of all Innate Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Innate Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Innate Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-10 | N/A | Other | Buy | 6,000 | N/A |
| 2024-01-02 | N/A | Other | Buy | 20,000 | N/A |
Peer Companies
